Posted inNews and Updates
Definium’s DT120 ODT Phase 3 GAD Trial Shows Positive Data
Definium’s DT120 ODT hits primary endpoints in Phase 3 GAD trials, showing promise as a fast-acting, easy-to-use treatment for generalized anxiety.
Posted inNews and Updates
Optimizing IRT Supply Management for Clinical Trial Success
Discover why advanced IRT supply management is essential for biotech success. Learn how to optimize clinical trial logistics and ensure patient safety.
Posted inNews and Updates
Biohaven Advances BHV-7000 Despite Unanswered FDA Query
Biohaven pushes BHV-7000 into pivotal trials despite unresolved FDA queries. Learn the implications for this epilepsy treatment and its regulatory path.
Posted inNews and Updates
Biohaven Advances BHV-7000 Despite Unanswered FDA Query
Biohaven moves BHV-7000 into pivotal trials for epilepsy despite pending regulatory questions. Discover the risks and clinical implications of this move.
Posted inNews and Updates
Sionna Therapeutics Launches Phase 2a Trial for New CF Drug
Sionna Therapeutics begins a Phase 2a trial testing the combination of SION-451 and SION-2222 to improve CFTR protein function in Cystic Fibrosis patients.
Posted inNews and Updates
US FDA Issues 7 Observations to Piramal Pharma Morpeth Site
Piramal Pharma addresses seven FDA observations at its UK Morpeth facility. Learn how the company is implementing CAPA to meet strict cGMP standards.
Posted inNews and Updates
Cere-Calm Trial: New Advancements in Neural Technology
Cere-Calm trials are advancing the future of neuro-modulation. Explore the latest updates on this clinical progress and its impact on neurological care.
Posted inNews and Updates
Rybrevant Treatment: A New Standard for EGFR Lung Cancer
Explore how Rybrevant is redefining standard care for EGFR-mutated lung cancer through bispecific antibody innovation and improved survival outcomes.
Posted inNews and Updates
enVista Envy IOL: Real-World Performance Data Revealed
New data from ESCRS 2026 confirms the enVista Envy IOL delivers consistent real-world outcomes, maintaining high visual quality despite minor refractive error.
Posted inNews and Updates
Rethinking Clinical Trial Design for Rare Kidney Cancer
Expert analysis reveals why traditional trial designs are failing rare kidney cancer patients and how adaptive research is changing the future of RCC.